Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Immatics presented updated ESMO data showing its IMA402 PRAME bispecific achieved a 32% confirmed response rate in PRAME-high melanoma with 12.5 months median duration of response and 91% one-year overall survival. The IMA203CD8 PRAME cell therapy showed deep activity across solid tumors, with a 55% cORR and 8.4 months median DOR in heavily pretreated gynecologic cancers at clinically relevant doses, plus an overall 41% cORR across tumor types. Both programs showed favorable, manageable safety profiles with no treatment-related Grade 5 events.
Key figures
- Drug Name
- IMA402; IMA203CD8
- Phase Of Trial
- Phase 1b (IMA402); Phase 1 (IMA203CD8)
- Ima402 dcr
- 63%
- Ima203cd8 dcr
- 82%
- Ima203cd8 orr all
- 51%
- Ima203cd8 corr all
- 41%
- Ima402 corr rp2d overall
- 25%
- Patients enrolled ima402
- 126
- Ima402 corr all prame high
- 32%
- Ima402 median dor melanoma
- 12.5 months
- Patients enrolled ima203cd8
- 98
- Ima402 corr prame high melanoma
- 32%
- Ima203cd8 median dor gynecologic
- 8.4 months
- Ima203cd8 median pfs gynecologic
- 5.8 months
- Ima402 1yr os prame high melanoma
- 91%
- Ima203cd8 orr gynecologic high dose
- 60%
- Ima203cd8 corr gynecologic high dose
- 55%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.